Please login to the form below

Not currently logged in
Email:
Password:

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

Gilead Sciences

Gilead Sciences has settled a patent dispute with Teva over its HIV and hepatitis drug Viread ahead of a US court case to test the strength of its intellectual property.

No financial terms of the settlement have been disclosed, but according to a Gilead statement, Teva has agreed to hold off on launching a generic version of Viread (tenofovir disoproxil fumarate) until December 15, 2017, when the US patent on the drug expires.

The litigation between the two companies on the validity of Gilead's Viread patent had been due to come to trial later today in the District Court for the Southern District of New York.

Tenofovir disoproxil fumarate has been a massive success for Gilead since it first launched in 2001, both in the Viread brand and as a component of the company's combination treatments for HIV and hepatitis B.

Viread achieved sales of $850m last year. Meanwhile Gilead's entire antiviral franchise of five products - all of which contain the active ingredient - brought in $8.14bn out of total product sales of $9.40bn.

The deal also buys time for Gilead to bring its Viread follow-up tenofovir alafenamide fumarate (TAF) to market. TAF entered the phase III testing stage last year and has been designed to reduce some of the side effects of its parent compound including the risk of renal impairment and bone thinning.

"This settlement removes some uncertainty and minimises further distraction and investment of human and financial resources associated with this litigation," said Gilead's chief operating officer John Milligan in a statement.

Previously, Gilead has successfully defended its Viread patent estate in US court cases which took place in 2008 and 2010.

20th February 2013

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics